Cargando…

PM(2.5) induced liver lipid metabolic disorders in C57BL/6J mice

PM(2.5) can cause adverse health effects via several pathways, such as inducing pulmonary and systemic inflammation, penetration into circulation, and activation of the autonomic nervous system. In particular, the impact of PM(2.5) exposure on the liver, which plays an important role in metabolism a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chenxiao, Ma, Tengfei, Liu, Chang, Ma, Ding, Wang, Jian, Liu, Meng, Ran, Jinjun, Wang, Xueting, Deng, Xiaobei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539470/
https://www.ncbi.nlm.nih.gov/pubmed/37780625
http://dx.doi.org/10.3389/fendo.2023.1212291
_version_ 1785113508353933312
author Zhang, Chenxiao
Ma, Tengfei
Liu, Chang
Ma, Ding
Wang, Jian
Liu, Meng
Ran, Jinjun
Wang, Xueting
Deng, Xiaobei
author_facet Zhang, Chenxiao
Ma, Tengfei
Liu, Chang
Ma, Ding
Wang, Jian
Liu, Meng
Ran, Jinjun
Wang, Xueting
Deng, Xiaobei
author_sort Zhang, Chenxiao
collection PubMed
description PM(2.5) can cause adverse health effects via several pathways, such as inducing pulmonary and systemic inflammation, penetration into circulation, and activation of the autonomic nervous system. In particular, the impact of PM(2.5) exposure on the liver, which plays an important role in metabolism and detoxification to maintain internal environment homeostasis, is getting more attention in recent years. In the present study, C57BL/6J mice were randomly assigned and treated with PM(2.5) suspension and PBS solution for 8 weeks. Then, hepatic tissue was prepared and identified by metabolomics analysis and transcriptomics analysis. PM(2.5) exposure can cause extensive metabolic disturbances, particularly in lipid and amino acids metabolic dysregulation.128 differential expression metabolites (DEMs) and 502 differently expressed genes (DEGs) between the PM(2.5) exposure group and control group were detected. The Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses showed that DEGs were significantly enriched in two disease pathways, non-alcoholic fatty liver disease (NAFLD) and type II diabetes mellitus (T2DM), and three signaling pathways, which are TGF-beta signaling, AMPK signaling, and mTOR signaling. Besides, further detection of acylcarnitine levels revealed accumulation in liver tissue, which caused restricted lipid consumption. Furthermore, lipid droplet accumulation in the liver was confirmed by Oil Red O staining, suggesting hepatic steatosis. Moreover, the aberrant expression of three key transcription factors revealed the potential regulatory effects in lipid metabolic disorders, the peroxisomal proliferative agent-activated receptors (PPARs) including PPARα and PPARγ is inhibited, and the activated sterol regulator-binding protein 1 (SREBP1) is overexpressed. Our results provide a novel molecular and genetic basis for a better understanding of the mechanisms of PM(2.5) exposure-induced hepatic metabolic diseases, especially in lipid metabolism.
format Online
Article
Text
id pubmed-10539470
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105394702023-09-30 PM(2.5) induced liver lipid metabolic disorders in C57BL/6J mice Zhang, Chenxiao Ma, Tengfei Liu, Chang Ma, Ding Wang, Jian Liu, Meng Ran, Jinjun Wang, Xueting Deng, Xiaobei Front Endocrinol (Lausanne) Endocrinology PM(2.5) can cause adverse health effects via several pathways, such as inducing pulmonary and systemic inflammation, penetration into circulation, and activation of the autonomic nervous system. In particular, the impact of PM(2.5) exposure on the liver, which plays an important role in metabolism and detoxification to maintain internal environment homeostasis, is getting more attention in recent years. In the present study, C57BL/6J mice were randomly assigned and treated with PM(2.5) suspension and PBS solution for 8 weeks. Then, hepatic tissue was prepared and identified by metabolomics analysis and transcriptomics analysis. PM(2.5) exposure can cause extensive metabolic disturbances, particularly in lipid and amino acids metabolic dysregulation.128 differential expression metabolites (DEMs) and 502 differently expressed genes (DEGs) between the PM(2.5) exposure group and control group were detected. The Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses showed that DEGs were significantly enriched in two disease pathways, non-alcoholic fatty liver disease (NAFLD) and type II diabetes mellitus (T2DM), and three signaling pathways, which are TGF-beta signaling, AMPK signaling, and mTOR signaling. Besides, further detection of acylcarnitine levels revealed accumulation in liver tissue, which caused restricted lipid consumption. Furthermore, lipid droplet accumulation in the liver was confirmed by Oil Red O staining, suggesting hepatic steatosis. Moreover, the aberrant expression of three key transcription factors revealed the potential regulatory effects in lipid metabolic disorders, the peroxisomal proliferative agent-activated receptors (PPARs) including PPARα and PPARγ is inhibited, and the activated sterol regulator-binding protein 1 (SREBP1) is overexpressed. Our results provide a novel molecular and genetic basis for a better understanding of the mechanisms of PM(2.5) exposure-induced hepatic metabolic diseases, especially in lipid metabolism. Frontiers Media S.A. 2023-09-14 /pmc/articles/PMC10539470/ /pubmed/37780625 http://dx.doi.org/10.3389/fendo.2023.1212291 Text en Copyright © 2023 Zhang, Ma, Liu, Ma, Wang, Liu, Ran, Wang and Deng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Zhang, Chenxiao
Ma, Tengfei
Liu, Chang
Ma, Ding
Wang, Jian
Liu, Meng
Ran, Jinjun
Wang, Xueting
Deng, Xiaobei
PM(2.5) induced liver lipid metabolic disorders in C57BL/6J mice
title PM(2.5) induced liver lipid metabolic disorders in C57BL/6J mice
title_full PM(2.5) induced liver lipid metabolic disorders in C57BL/6J mice
title_fullStr PM(2.5) induced liver lipid metabolic disorders in C57BL/6J mice
title_full_unstemmed PM(2.5) induced liver lipid metabolic disorders in C57BL/6J mice
title_short PM(2.5) induced liver lipid metabolic disorders in C57BL/6J mice
title_sort pm(2.5) induced liver lipid metabolic disorders in c57bl/6j mice
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539470/
https://www.ncbi.nlm.nih.gov/pubmed/37780625
http://dx.doi.org/10.3389/fendo.2023.1212291
work_keys_str_mv AT zhangchenxiao pm25inducedliverlipidmetabolicdisordersinc57bl6jmice
AT matengfei pm25inducedliverlipidmetabolicdisordersinc57bl6jmice
AT liuchang pm25inducedliverlipidmetabolicdisordersinc57bl6jmice
AT mading pm25inducedliverlipidmetabolicdisordersinc57bl6jmice
AT wangjian pm25inducedliverlipidmetabolicdisordersinc57bl6jmice
AT liumeng pm25inducedliverlipidmetabolicdisordersinc57bl6jmice
AT ranjinjun pm25inducedliverlipidmetabolicdisordersinc57bl6jmice
AT wangxueting pm25inducedliverlipidmetabolicdisordersinc57bl6jmice
AT dengxiaobei pm25inducedliverlipidmetabolicdisordersinc57bl6jmice